Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07. Januar 2025 08:00 ET
|
Bioventus, Inc.
DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will...
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
02. Januar 2025 08:00 ET
|
Bioventus, Inc.
DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has...
Bioventus Reports Third Quarter Financial Results
05. November 2024 07:30 ET
|
Bioventus, Inc.
Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to...
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
29. Oktober 2024 07:30 ET
|
Bioventus, Inc.
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report...
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
01. Oktober 2024 09:00 ET
|
Bioventus, Inc.
DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a...
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
07. August 2024 16:15 ET
|
Bioventus, Inc.
DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief...
Bioventus Reports Second Quarter Financial Results
06. August 2024 07:30 ET
|
Bioventus, Inc.
Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9%Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bpsCash from Operations of $15.2 million Increased 40.5%Raising Full-Year 2024...
Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
30. Juli 2024 07:30 ET
|
Bioventus, Inc.
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report...
Bioventus Reports First Quarter Financial Results
07. Mai 2024 07:00 ET
|
Bioventus, Inc.
Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic PrioritiesAccelerated First Quarter Revenue Growth by 8.7%, Organic Growth* by 15.3%Gross...
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
29. April 2024 07:30 ET
|
Bioventus, Inc.
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report...